Lexicon Pharmaceuticals | LXRX - Assets

Stock Price
1.31
Daily Change
0 0%
Monthly
5.65%
Yearly
66.90%
Q1 Forecast
2.01

Lexicon Pharmaceuticals reported $225.58M in Assets for its fiscal quarter ending in June of 2025.





Assets Change Date
Abbott USD 84.18B 182M Sep/2025
Acadia Pharmaceuticals USD 1.33B 105.22M Sep/2025
Agios Pharmaceuticals USD 1.3B 88.48M Dec/2025
Akebia Therapeutics USD 364.15M 18.56M Sep/2025
Alnylam Pharmaceuticals USD 4.97B 114.67M Dec/2025
AstraZeneca USD 114.07B 382M Dec/2025
BioMarin Pharmaceutical USD 7.61B 158.53M Sep/2025
Coherus Biosciences USD 516.52M 77.05M Sep/2025
Eli Lilly USD 112.48B 2.46B Dec/2025
Esperion Therapeutics USD 364.02M 16.93M Sep/2025
Halozyme Therapeutics USD 2.22B 167.33M Sep/2025
Illumina USD 6.64B 467M Dec/2025
Insmed USD 2.36B 119.12M Sep/2025
Ironwood Pharmaceuticals USD 396.06M 53.12M Sep/2025
J&J USD 199.21B 6.39B Dec/2025
Lexicon Pharmaceuticals USD 225.58M 72.09M Jun/2025
MacroGenics USD 270.76M 25.34M Sep/2025
MannKind USD 494.64M 82.94M Sep/2025
Merck USD 129.55B 12.02B Sep/2025
Moderna USD 12.34B 203M Dec/2025
Novartis USD 107.29B 2.89B Sep/2025
PTC Therapeutics USD 2.64B 9.54M Sep/2025
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Sarepta Therapeutics USD 3.49B 186.38M Sep/2025
Thermo Fisher Scientific USD 110.34B 7.32B Dec/2025
Ultragenyx Pharmaceutical USD 1.53B 341.56M Dec/2025
United Therapeutics USD 7.35B 556.9M Sep/2025
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025